Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2025

Genmab — Januar 2025

Planlagt Fastgjort Låst Flyttet Genmab
702 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #691

    !! Tivdak (tisotumab vedotin) received a positive opinion from the CHMP for the treatment of recurrent or metastatic cervical cancer. !! https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2025

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #692

      Link Preview Image
      Tivdak | European Medicines Agency (EMA)

      favicon

      European Medicines Agency (EMA) (www.ema.europa.eu)

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #693

        Fra MW" Der ser ud til, at kræftmidlet Tivdak, som Genmab står bag sammen med partneren Pfizer, kan blive markedsført i Europa til behandling af tilbagevendende eller metastatisk livmoderhalskræft.

        Ifølge de europæiske sundhedsmyndigheder, EMA, er det komitéen for humanmedicinske lægemidler (CHMP), der har nikket ja.

        • Fordelene ved Tivdak er dets overlegenhed med hensyn til at forlænge overlevelsen og overlevelsen uden sygdomsprogression sammenlignet med kemoterapi, skriver EMA i meddelelsen.
        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #694

          Med godkendelsen er vejen mere eller mindre banet for en endelig godkendelse. Beslutningen om en endelig markedsføringsgodkendelse skal træffes af EU-Kommissionen, som normalt følger indstillingen fra komitéen.

          Tivdak markedsføres i forvejen i USA som behandling af tilbagevendende eller metastatisk livmoderhalskræft. Tivdak går også under navnet Tisotumab Vedotin."

          1 Reply Last reply
          0
          • P Offline
            P Offline
            ProinvestorNEWS
            wrote on sidst redigeret af
            #695

            Genmab får potentiel godkendelse af kræftmidlet Tivdak af europæiske sundhedsmyndigheder https://proinvestor.com/investornyt/1271975/genmab-far-potentiel-godkendelse-af-kraeftmidlet-tivdak-af-europaeiske-sundhedsmyndigheder

            1 Reply Last reply
            0
            • V Offline
              V Offline
              Vitus
              wrote on sidst redigeret af
              #696

              Så kom der da 2 gode nyheder, og Genmab stiger fantastiske 0,5%….det er da flot 🙂

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #697

                ABBVIE Epkinly Q4 '24 US 18 Intl 22 Tot 40 , Full year 60

                86

                146

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #698

                  so that's a flat quarter, similar to Roche, was also flattish

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #699

                    ; Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories. > so lets estimate
                    we end up around $280mn for 2024 total vs Roch ~$267mn

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #700

                      Som en sidebemærkning er Genmab nr 8 blandt de 50 største selskabskatteydere i 2023 med 1,273 mia. kr. Størst er selvfølgelig Novo Holding med knap 15,3 mia. kr https://borsen.dk/nyheder/virksomheder/sky-energimilliardaer-og-nordjysk-storfisker-stryger-frem-pa-skatteliste?b_source=borsen&b_medium=row_0&b_campaign=news_2

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #701

                        Genmab
                        @Genmab
                        Genmab and academia partners are proud to share a review in Seminars in Immunology on optimizing antibody therapies through enhanced complement activation.
                        https://x.com/Genmab/status/1885415198938296560

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #702

                          some extra attention to this article with focus on hexamerization in anticipation of.....

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #703

                            EL, you had couple of days ago a link to a conference/seminar on hexa….slmething in March. Cant find your link :-), please

                            1 Reply Last reply
                            0

                            Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                            Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                            With your input, this post could be even better 💗

                            Tilmeld Log ind
                            Svar
                            • Svar som emne
                            Login for at svare
                            • Ældste til nyeste
                            • Nyeste til ældste
                            • Most Votes


                            • Log ind

                            • Har du ikke en konto? Tilmeld

                            • Login or register to search.
                            Powered by NodeBB Contributors
                            • First post
                              Last post
                            0
                            • Kategorier
                            • Seneste
                            • Etiketter
                            • Populære
                            • Verden
                            • Bruger
                            • Grupper